Daratumumab for Posttransplant Autoimmune Hemolytic Anemia
Yaqeen Abduallah
Transplant and Cellular Therapy Program, Division of Hematology, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada
Search for more papers by this authorMichael Kennah
Transplant and Cellular Therapy Program, Division of Hematology, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada
Search for more papers by this authorConnor Prince
Transplant and Cellular Therapy Program, Division of Hematology, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada
Search for more papers by this authorAshish Masurekar
Transplant and Cellular Therapy Program, Division of Hematology, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada
Search for more papers by this authorNatasha Kekre
Transplant and Cellular Therapy Program, Division of Hematology, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada
Search for more papers by this authorCorresponding Author
Ram Vasudevan Nampoothiri
Transplant and Cellular Therapy Program, Division of Hematology, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada
Correspondence:
Ram Vasudevan Nampoothiri ([email protected])
Search for more papers by this authorYaqeen Abduallah
Transplant and Cellular Therapy Program, Division of Hematology, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada
Search for more papers by this authorMichael Kennah
Transplant and Cellular Therapy Program, Division of Hematology, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada
Search for more papers by this authorConnor Prince
Transplant and Cellular Therapy Program, Division of Hematology, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada
Search for more papers by this authorAshish Masurekar
Transplant and Cellular Therapy Program, Division of Hematology, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada
Search for more papers by this authorNatasha Kekre
Transplant and Cellular Therapy Program, Division of Hematology, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada
Search for more papers by this authorCorresponding Author
Ram Vasudevan Nampoothiri
Transplant and Cellular Therapy Program, Division of Hematology, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada
Correspondence:
Ram Vasudevan Nampoothiri ([email protected])
Search for more papers by this authorFunding: The authors received no specific funding for this work.
References
- 1N. Desai, A. Viswabandya, D. D. H. Kim, et al., “Daratumumab in the Management of Red Cell Aplasia Following Allogeneic Hematopoietic Stem Cell Transplantation,” European Journal of Haematology 114, no. 2 (2025): 310–314, https://doi.org/10.1111/ejh.14341.
- 2M. Jalink, C. F. Jacobs, J. Khwaja, et al., “Daratumumab Monotherapy in Refractory Warm Autoimmune Hemolytic Anemia and Cold Agglutinin Disease,” Blood Advances 8, no. 11 (2024): 2622–2634.
- 3W. Barcellini, B. Fattizzo, and A. Zaninoni, “Management of Refractory Autoimmune Hemolytic Anemia After Allogeneic Hematopoietic Stem Cell Transplantation: Current Perspectives,” Journal of Blood Medicine 10 (2019): 265–278.
- 4S. Giammarco, M. A. Limongiello, L. Di Marino, et al., “The Role of Daratumumab in Complications Post-Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Prospective Study on PRCA and AIHA,” Bone Marrow Transplantation 60, no. 3 (2025): 305–309, https://doi.org/10.1038/s41409-024-02479-w.
- 5C. I. Chapuy, R. M. Kaufman, E. P. Alyea, and J. M. Connors, “Daratumumab for Delayed Red-Cell Engraftment After Allogeneic Transplantation,” New England Journal of Medicine 379, no. 19 (2018): 1846–1850.
- 6M. Wang, W. Wang, A. Abeywardane, et al., “Autoimmune Hemolytic Anemia After Allogeneic Hematopoietic Stem Cell Transplantation: Analysis of 533 Adult Patients Who Underwent Transplantation at King's College Hospital,” Biology of Blood and Marrow Transplantation 21, no. 1 (2015): 60–66.
- 7M. D. Kruizinga, M. J. D. van Tol, V. Bekker, et al., “Risk Factors, Treatment, and Immune Dysregulation in Autoimmune Cytopenia After Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients,” Biology of Blood and Marrow Transplantation 24, no. 4 (2018): 772–778.
- 8C. Schuetz, M. Hoenig, D. Moshous, et al., “Daratumumab in Life-Threatening Autoimmune Hemolytic Anemia Following Hematopoietic Stem Cell Transplantation,” Blood Advances 2, no. 19 (2018): 2550–2553.
- 9I. Ahmed, J. Teruya, C. Murray-Krezan, and R. Krance, “The Incidence of Autoimmune Hemolytic Anemia in Pediatric Hematopoietic Stem Cell Recipients Post-First and Post-Second Hematopoietic Stem Cell Transplant,” Pediatric Transplantation 19, no. 4 (2015): 391–398.
Citing Literature
